Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
40 hedge funds and large institutions have $5.76M invested in Codiak BioSciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 13 closing their positions.
17% less funds holding
Funds holding: 48 → 40 (-8)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
58% less capital invested
Capital invested by funds: $13.6M → $5.76M (-$7.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$153K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.4K |
| 3 |
VF
Virtu Financial
New York
|
+$34.5K |
| 4 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$28.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$22.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$782K |
| 2 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
-$767K |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$382K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$176K |
| 5 |
BlackRock
New York
|
-$82.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| – | +$179 | +272 | +716% |
|
CDAK Hedge Fund Activity: Q4 2022 in Review
40 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q4 2022, worth a combined $5.76M — down 58% from $13.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CDAK and 6 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $153K. The largest seller was Armistice Capital, exiting entirely with an estimated $782K sold.
- 40 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q4 2022, down from 48 in Q3 2022.
- Funds reported $5.76M of Codiak BioSciences, Inc. Common Stock stock for Q4 2022, down 58% quarter-over-quarter.
- 6 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -7 holders.
- The largest Codiak BioSciences, Inc. Common Stock buyer in Q4 2022 was Renaissance Technologies, an estimated $153K added.
- The largest Codiak BioSciences, Inc. Common Stock seller in Q4 2022 was Armistice Capital, an estimated $782K sold.
Based on aggregated 13F filings for Q4 2022.